Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Frontiers in Immunology|November 7, 2022
Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancerPeng Jin, Menglin Bai, Jie Liu, et al.
Cancer Letters|January 30, 2025
Synergistic enhancement of radio-immunotherapy efficacy by IL-15 via macrophage activation and memory T cell responsePeng Jin, Menglin Bai, Ji Li, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|November 8, 2018
TPPP3 Promotes Cell Proliferation, Invasion and Tumor Metastasis via STAT3/ Twist1 Pathway in Non-Small-Cell Lung CarcinomaYintao Li, Menglin Bai, Yali Xu, et al.
Cell Communication and Signaling : CCS|May 24, 2023
Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientationsLeilei Wu, Zhenshan Zhang, Menglin Bai, et al.
Cancer Letters|July 8, 2021
PET/CT metabolic patterns in systemic immune activation: A new perspective on the assessment of immunotherapy response and efficacyPeng Jin, Jianing Li, Yingtao Meng, et al.
Cancer Letters|July 30, 2024
Irradiated tumor cell-released microparticles enhance the therapeutic efficacy of PD-1 inhibitors by promoting M1-TAMs polarization in NSCLC brain metastasesJi Li, Menglin Bai, Wenxiao Jia, et al.
Frontiers in Immunology|March 17, 2022
Efficacy of Immune Checkpoint Inhibitors in Patients With EGFR Mutated NSCLC and Potential Risk Factors Associated With Prognosis: A Single Institution ExperienceMenglin Bai, Weiqing Wang, Xuetian Gao, et al.
Cancer Letters|January 26, 2024
PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutationXiaoyu Hu, Mengyu Zhao, Menglin Bai, et al.
International Immunopharmacology|February 16, 2024
Survival outcomes of targeted and immune consolidation therapies in locally advanced unresectable lung adenocarcinomaXiaohan Wang, Xue Meng, Guoxin Cai, et al.
Cancer Medicine|October 30, 2025
Metabolic Reprogramming in Lung Cancer: Hallmarks, Mechanisms, and Targeted Strategies to Overcome Immune ResistanceYi Chen, Menglin Bai, Ming Liu, et al.
Pageof 3